These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 22628425)
1. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Ganti S; Taylor SL; Abu Aboud O; Yang J; Evans C; Osier MV; Alexander DC; Kim K; Weiss RH Cancer Res; 2012 Jul; 72(14):3471-9. PubMed ID: 22628425 [TBL] [Abstract][Full Text] [Related]
2. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA. Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093 [TBL] [Abstract][Full Text] [Related]
3. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263 [TBL] [Abstract][Full Text] [Related]
4. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065 [TBL] [Abstract][Full Text] [Related]
5. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma. Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842 [TBL] [Abstract][Full Text] [Related]
6. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights. Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388 [TBL] [Abstract][Full Text] [Related]
7. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis. Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison. Leuthold P; Schaeffeler E; Winter S; Büttner F; Hofmann U; Mürdter TE; Rausch S; Sonntag D; Wahrheit J; Fend F; Hennenlotter J; Bedke J; Schwab M; Haag M J Proteome Res; 2017 Feb; 16(2):933-944. PubMed ID: 27992229 [TBL] [Abstract][Full Text] [Related]
9. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. Kim K; Taylor SL; Ganti S; Guo L; Osier MV; Weiss RH OMICS; 2011 May; 15(5):293-303. PubMed ID: 21348635 [TBL] [Abstract][Full Text] [Related]
10. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection. Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228 [TBL] [Abstract][Full Text] [Related]
12. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Khamis MM; Adamko DJ; El-Aneed A Mass Spectrom Rev; 2017 Mar; 36(2):115-134. PubMed ID: 25881008 [TBL] [Abstract][Full Text] [Related]
13. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma. Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988 [TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593 [TBL] [Abstract][Full Text] [Related]
15. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651 [TBL] [Abstract][Full Text] [Related]
16. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease. Peng J; Guo K; Xia J; Zhou J; Yang J; Westaway D; Wishart DS; Li L J Proteome Res; 2014 Oct; 13(10):4457-69. PubMed ID: 25164377 [TBL] [Abstract][Full Text] [Related]
17. High-throughput metabolomics for discovering metabolic biomarkers from intestinal tumorigenesis in APC Guo XD; Liu L; Xiao HY J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():131-139. PubMed ID: 30316137 [TBL] [Abstract][Full Text] [Related]
18. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma. DiNatale RG; Sanchez A; Hakimi AA; Reznik E Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438 [TBL] [Abstract][Full Text] [Related]
19. Identification of activation of tryptophan-NAD Wang L; Yao D; Urriola PE; Hanson AR; Saqui-Salces M; Kerr BJ; Shurson GC; Chen C J Nutr Biochem; 2018 Jul; 57():255-267. PubMed ID: 29800812 [TBL] [Abstract][Full Text] [Related]